Rana R. McKay, MD, of @UCSDCRCERA, discusses key clinical trials that have shifted the treatment paradigms in metastatic castration-resistant prostate cancer, nonmetastatic castration-resistant prostate cancer, and advanced prostate cancer. #pcsm https://t.co/s1Z1VzzlvK

Blocking tumour protein FAK releases checkpoint brake making #ovariancancer susceptible to #immunotherapy. Image and research by @DOzmadenci et al @UCSDCancer @UCSD_ObGyn @UCSDCRCERA in @PNASNews. Read more on https://t.co/zI4QdijuQb with @MRC_LMS and @AntDLewis

Jennifer M. Matro, MD, of @UCSDCRCERA, provides an in-depth look at clinical trials that have added to the breast cancer paradigm and how she is interpreting the findings for clinical practice #bcsm https://t.co/PZFoEdrSTK

Sandip P. Patel, MD, of @UCSDCRCERA, discusses frontline immunotherapy in advanced NSCLC, the treatment of patients with EGFR- and KRAS G12C–mutant and EGFR exon 20 insertion–positive disease, and the management of stage III disease #lcsm https://t.co/2Z6WdFlDqh

Jennifer M. Matro, MD, of @UCSDCRCERA, provides an in-depth look at clinical trials that have added to the breast cancer paradigm and how she is interpreting the findings for clinical practice #bcsm https://t.co/VYsJHLMBIg

Sandip P. Patel, MD, of @UCSDCRCERA, frontline immunotherapy in advanced NSCLC, the treatment of patients with EGFR- and KRAS G12C–mutant and EGFR exon 20 insertion–positive disease, and the management of stage III disease #lcsm https://t.co/4gpxJUkbqO

Thomas Kipps, MD, PhD, of @UCSDCRCERA, discusses navigating treatment regimens in CLL and MCL, the success of brentuximab vedotin in Hodgkin lymphoma, choosing between TKIs in CML, and the importance of transfusion independence in MDS #lymsm #leusm https://t.co/zmjQrieQOK

Sandip P. Patel, MD, of @UCSDCRCERA, frontline immunotherapy in advanced NSCLC, the treatment of patients with EGFR- and KRAS G12C–mutant and EGFR exon 20 insertion–positive disease, and the management of stage III disease #lcsm https://t.co/aTjHDco7z9

Jennifer M. Matro, MD, of @UCSDCRCERA, provides an in-depth look at clinical trials that have added to the breast cancer paradigm and how she is interpreting the findings for clinical practice #bcsm https://t.co/5SYMQIez5g

HOLD THE DATE: September 9, 2022 33rd Annual Mahajani Symposium focusing on TUMOR DORMANCY. Amazing line up including @GhajarLab @lab_gomes @luciaborriell @Giancotti_Lab @megeblad @JF_CoteLab @alvarezlabhutch and Kay Yeung. Co-hosted by @salkinstitute @UCSDCRCERA @SBPCancerCenter

Benjamin Heyman, MD, of @UCSDCRCERA, discusses the phase 3 SYMPATICO trial examining the combination of ibrutinib and venetoclax vs ibrutinib alone in patients with relapsed or refractory mantle cell lymphoma #lymsm https://t.co/5WMxZbDTif

Sandip P. Patel, MD, of @UCSDCRCERA, discusses frontline immunotherapy in advanced NSCLC, the treatment of patients with EGFR- and KRAS G12C–mutant and EGFR exon 20 insertion–positive disease, and the management of stage III disease #lcsm https://t.co/Ve0KLAYqpJ

Please see select Gastrointestinal Stromal Tumor (#GIST) #Sarcoma abstracts presented at @ASCO #ASCO22 @ConquerCancerFd @ASCOPost by @SteveBialickDO @SylvesterCancer @pawel_sobczuk @MSCActions @VHIO @im_schaefer @DanaFarber @JasonSicklick @UCSDCRCERA

Join us on April 20 for the #LungCancerSeries webinar on Management of Patients with #ALK #Mutated #NSCLC. With Moderator @HatimHusainMD and panelists @oncoOuLungCA and @JoelNealMD Free registration visit: https://t.co/6ywvER69hp

Thomas Kipps, MD, PhD, of @UCSDCRCERA discusses navigating treatment regimens in CLL and MCL, the success of brentuximab vedotin in Hodgkin lymphoma, choosing between TKIs in CML, and the importance of transfusion independence in MDS #lymsm #leusm https://t.co/zmjQrieQOK

You can still support cancer research and donate to our Pharm team UCSD! Link to click: https://t.co/Sur6hRBxJx Thank you! @SilvioGutkind @PedalSD

Benjamin Heyman, MD, of @UCSDCRCERA, discusses future therapeutic directions in mantle cell lymphoma #lymsm https://t.co/gce2HMr21X

ARE YOU READY???? Let's go! Ride/run/walk/spin Over $15 million raised to date to fund 78 innovative research grants in all types of cancer. @PedalSD @sbpdiscovery @radychildrens @scrippsresearch @UCSDCRCERA @ljiresearch https://t.co/TtW6NR39pl

Calling all physicians, scientists, nurses, public health experts interested in cancer: register now for the inaugural Moores Cancer Center Oncology CME event! #Cancer #CancerResearch #oncology #CME @UCSanDiegoDRM @UCSDPharm @UCSDHealth @UCSDHealthAging https://t.co/czWzlmEHQ2